Truist Securities Reiterates Buy on Gilead Sciences, Raises Price Target to $157

Benzinga Newsdesk www.benzinga.com Positive 72.3%

Neg 0% Neu 0% Pos 72.3%

Truist Securities analyst Gregory Renza reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $157.